Addressing Polycystic Ovary Syndrome to Mitigate Cardiovascular Disease Risk

Overview

Polycystic ovary syndrome (PCOS) significantly increases cardiovascular disease (CVD) risk, including coronary artery disease and myocardial infarction, even in non-obese women. Conventional therapies show limited benefit in reducing CVD events, highlighting the need for alternative treatment strategies.

Background

PCOS affects 5–10% of women of reproductive age and is the most common hormonal disorder in this population. It is associated with cardiometabolic abnormalities such as dyslipidaemia, insulin resistance, systemic inflammation, and endothelial dysfunction, all contributing to elevated CVD risk. The impact of PCOS on CVD, particularly among non-obese women, has been underexplored. Recent research from the UK Biobank provides new insights into the long-term cardiovascular risks in women with PCOS.

Data Highlights

Key Findings

• Women with PCOS have a 77% increased risk of cardiovascular disease compared to controls.
• Non-obese women with PCOS exhibit over a two-fold increased risk of coronary artery disease and myocardial infarction, independent of genetic risk factors.
• Common PCOS treatments such as hormonal contraceptives, metformin, and anti-androgens do not significantly reduce CVD outcomes.
• Obesity can mimic PCOS symptoms, complicating diagnosis especially in obese women; PCOS is a diagnosis of exclusion requiring thorough evaluation.
• Hormonal imbalances in PCOS include low estradiol, high luteinizing hormone, and elevated testosterone, which contribute to increased CVD risk.
• Emerging therapies like estradiol and progesterone supplementation, GLP-1 receptor agonists, and lifestyle interventions show promise for reducing CVD risk in PCOS women.

Clinical Implications

Clinicians should recognize that non-obese women with PCOS remain at high risk for cardiovascular events despite conventional therapies. Comprehensive evaluation to confirm PCOS diagnosis is essential, particularly to exclude obesity-related mimics. Alternative therapeutic approaches, including hormone supplementation and GLP-1 receptor agonists combined with lifestyle modifications, warrant consideration to improve cardiovascular outcomes in this population.

Conclusion

PCOS significantly elevates cardiovascular risk across both obese and non-obese women, with current treatments insufficient to mitigate this risk. Future research and clinical practice should focus on novel hormonal and metabolic therapies alongside lifestyle optimization to better protect cardiovascular health in women with PCOS.

References

1. Zhao et al. 2022 -- Nonobese young females with polycystic ovary syndrome are at high risk for long-term cardiovascular disease